Genprex Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating REQORSA® Immunogene Therapy in Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting ...Middle East

Results Show Combination of REQORSA® and Tagrisso® was Well Tolerated at All Three Dose Levels of Phase 1 Trial with Encouraging Evidence of Efficacy Observed AUSTIN, Texas, May 25, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene...

Hence then, the article about genprex publishes positive clinical data from phase 1 portion of acclaim 1 clinical trial evaluating reqorsa immunogene therapy in non small cell lung cancer at the 2023 asco annual meeting was published today ( Friday 26/05/2023 - 12:01 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Genprex Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating REQORSA® Immunogene Therapy in Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting )

Also on site :

• Watch last video of ‘All That’ star Kianna Underwood who died in hit-and-run at 33
• AI cloud startup Runpod hits $120M in ARR — and it started with a Reddit post  
• Tim McGraw Teases New Music With Cryptic Photos & Fans Can't Keep Their Cool